Roche leads healthcare sector in key sustainability index for fourth consecutive year

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the fourth year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on best-in-class approach in environmental, social and economic performance. The indexes serve as benchmarks for investors who integrate sustainability considerations into their portfolios.

"Roche's ranking as the most sustainable healthcare builds on the continued efforts do business in a way that benefits all our stakeholders. Roche is committed to engaging with communities, patients and public health in a way that creates long-term value for everyone" said Severin Schwan, CEO of Roche. "In particular, we have established goals in diversity and energy savings that are integrated into the incentives for the company's management and leadership to help drive our activities in these areas. We are also launching new initiatives to expand access to our innovative drugs in emerging markets to enable more people to benefit from our products, while continuing as an international leader in medicine and diagnostics research."

This year's DJSI assessment emphasized a number of Roche's efforts as a sustainable company. They include Roche's strategy which focuses on medical innovation and its personalised healthcare approach, which addresses healthcare efficiency and improves health outcomes. Roche's programmes on developing future leaders and respecting human rights were also recognised, together with the company's pilot programmes for differential pricing in developing countries that aim to expand the number of people able to access Roche medicines.

In 2009 Roche defined a number of five-year corporate goals, with Key Performance Indicators enabling it to measure the progress. Amongst them, Roche introduced a diversity objective to increase the percentage of women in key positions by at least 50 percent, plus an energy efficiency goal of a 10 percent reduction in energy consumption and an increase in energy efficiency by end of 2014.

About the Dow Jones Sustainability Indexes (DJSI)
The DJSI is the most widely accepted global assessment of how companies approach their social, economic and environmental responsibility. The DJS World Index tracks the performance of the top 10% of the 2500 largest companies in the Dow Jones Global Total Stock Market Index, while the DJS Europe Index tracks the performance of the top 20% of the 600 largest European companies that lead the field in terms of sustainability. Annual selection into the DJSI World and DJSI Europe follows a thorough analysis of corporate economic, environmental and social performance by Sustainable Asset Management (SAM), an investment specialist group focused exclusively on sustainability investing. They assess business management practices such as corporate governance, risk management, human resource practices, customer relations, stakeholder engagement and the quality of environmental reporting, in addition to sector-specific elements, such as strategies on access to medicines and innovation in R&D. Roche has been included in the DJSI World and Europe since 2004, and was named Supersector Leader in healthcare in 2009, in 2010 and in 2011.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Most Popular Now

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

Pfizer and BioNTech announce early positive data f…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT16...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Novartis resolves legacy litigation matters, final…

Novartis has finalized its previously disclosed agreement with the US Attorney's Office for the Southern District of New York, the New York State Attorney General, and re...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Newer variant of COVID-19-causing virus dominates …

Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission an...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...